Skip to content

Mannkind MNKD Issuance Costs Associated With Sale Of Future Royalties

Issuance Costs Associated With Sale Of Future Royalties at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.25M
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$0-100%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$17.34M-7.9%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$0
uniQure logo
uniQureQURE
$92.52M
Geron logo
GeronGERN
$3.91M-18.5%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:IssuanceCostsAssociatedWithSaleOfFutureRoyalties.

The official record: Mannkind’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's issuance costs associated with sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's issuance costs associated with sale of future royalties?
Mannkind (MNKD) reported issuance costs associated with sale of future royalties of $1.01M in Q4 2023.
What does issuance costs associated with sale of future royalties mean?
Represents the direct costs incurred to execute a financing arrangement involving the sale of future royalty streams. These costs typically include legal, accounting, and underwriting fees associated with monetizing future revenue rights. Monitoring these costs helps investors assess the efficiency of capital raising activities and the total cost of debt-like financing structures.